Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 34Polycystic Ovary Syndrome 2Infertility 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunction, Physiological 1Prostatic Intraepithelial Neoplasia 1Primary Dysautonomias 1Overweight 1Ovarian Neoplasms 1Oligomenorrhea 1Metabolic Syndrome 1Kidney Diseases 1Insulin Resistance 1Hypertension 1Hyperandrogenism 1Hirsutism 1Castration-resistant Prostate Cancer 1Carcinoma, Ovarian Epithelial 1Anovulation 1Amenorrhea 1Adenocarcinoma 1

Interventions

enzalutamide 4Abiraterone Acetate 2radium Ra 223 dichloride 1dactolisib 1abiraterone 1VT-464 1Prednisone 1NVP-BKM120 1Flutamide 1Crizotinib 1Control Groups 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Castration-resistant Prostate Cancer × Flutamide × Clear all
NCT02346578 2021-09-16

Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

Osaka City University

Phase 2 Completed
104 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡